TWI640515B - 選擇性ｎｒ２ｂ拮抗劑 - Google Patents
選擇性ｎｒ２ｂ拮抗劑 Download PDFInfo
- Publication number
- TWI640515B TWI640515B TW104100592A TW104100592A TWI640515B TW I640515 B TWI640515 B TW I640515B TW 104100592 A TW104100592 A TW 104100592A TW 104100592 A TW104100592 A TW 104100592A TW I640515 B TWI640515 B TW I640515B
- Authority
- TW
- Taiwan
- Prior art keywords
- fluoro
- pyrrolidin
- hydroxyphenyl
- mmol
- hexahydropyridin
- Prior art date
Links
- 108010038912 Retinoid X Receptors Proteins 0.000 title abstract description 14
- 102000034527 Retinoid X Receptors Human genes 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 114
- 150000003839 salts Chemical class 0.000 claims abstract description 14
- -1 hexahydropyridyl Chemical group 0.000 claims description 74
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 20
- 125000001424 substituent group Chemical group 0.000 claims description 14
- 125000000217 alkyl group Chemical group 0.000 claims description 13
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 7
- 125000001188 haloalkyl group Chemical group 0.000 claims description 7
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- 125000006181 4-methyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])C([H])([H])* 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 125000004639 dihydroindenyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims description 3
- UNVYDSCXINFREZ-BHDDXSALSA-N (3R)-3-[(3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl]-1-[(4-methylphenyl)methyl]pyrrolidin-2-one Chemical compound F[C@@H]1CN(CC[C@H]1C1=CC=C(C=C1)O)[C@H]1C(N(CC1)CC1=CC=C(C=C1)C)=O UNVYDSCXINFREZ-BHDDXSALSA-N 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 125000002393 azetidinyl group Chemical group 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims 4
- GWYUSNIRBPSYRB-UHFFFAOYSA-N 1-[(4-methylphenyl)methyl]pyrrolidin-2-one Chemical compound C1=CC(C)=CC=C1CN1C(=O)CCC1 GWYUSNIRBPSYRB-UHFFFAOYSA-N 0.000 claims 2
- 208000004296 neuralgia Diseases 0.000 claims 2
- 208000021722 neuropathic pain Diseases 0.000 claims 2
- 208000020401 Depressive disease Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 304
- 239000000203 mixture Substances 0.000 abstract description 77
- 239000003446 ligand Substances 0.000 abstract description 5
- 208000015114 central nervous system disease Diseases 0.000 abstract description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 216
- 238000005481 NMR spectroscopy Methods 0.000 description 149
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 126
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 120
- 239000002904 solvent Substances 0.000 description 108
- 229910052796 boron Inorganic materials 0.000 description 96
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 88
- 238000004808 supercritical fluid chromatography Methods 0.000 description 82
- 239000006184 cosolvent Substances 0.000 description 62
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 61
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 58
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 53
- 239000000543 intermediate Substances 0.000 description 48
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 45
- 239000012071 phase Substances 0.000 description 45
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 40
- 239000000047 product Substances 0.000 description 39
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 37
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 36
- 239000012043 crude product Substances 0.000 description 35
- 229910052739 hydrogen Inorganic materials 0.000 description 32
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 31
- 235000019439 ethyl acetate Nutrition 0.000 description 31
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 30
- 239000000243 solution Substances 0.000 description 30
- 238000010828 elution Methods 0.000 description 29
- 238000000926 separation method Methods 0.000 description 27
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 26
- 238000002953 preparative HPLC Methods 0.000 description 26
- 239000011541 reaction mixture Substances 0.000 description 26
- 239000000872 buffer Substances 0.000 description 22
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 21
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 20
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 19
- 239000003643 water by type Substances 0.000 description 18
- 239000008186 active pharmaceutical agent Substances 0.000 description 17
- 238000004128 high performance liquid chromatography Methods 0.000 description 16
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 16
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 15
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 15
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 15
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 14
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 14
- 230000015572 biosynthetic process Effects 0.000 description 14
- 239000003814 drug Substances 0.000 description 14
- 238000003786 synthesis reaction Methods 0.000 description 14
- 229940079593 drug Drugs 0.000 description 13
- 102100022630 Glutamate receptor ionotropic, NMDA 2B Human genes 0.000 description 12
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 12
- 239000012044 organic layer Substances 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 11
- 230000002829 reductive effect Effects 0.000 description 11
- 238000010898 silica gel chromatography Methods 0.000 description 11
- 239000011734 sodium Substances 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 238000000746 purification Methods 0.000 description 10
- JDALTJHKFDANJI-UHFFFAOYSA-N 1-benzyl-3-bromopyrrolidin-2-one Chemical compound O=C1C(Br)CCN1CC1=CC=CC=C1 JDALTJHKFDANJI-UHFFFAOYSA-N 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 9
- 229910021529 ammonia Inorganic materials 0.000 description 9
- XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 8
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 8
- 239000005695 Ammonium acetate Substances 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 8
- 235000019257 ammonium acetate Nutrition 0.000 description 8
- 229940043376 ammonium acetate Drugs 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 7
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 7
- 230000027455 binding Effects 0.000 description 7
- 238000002955 isolation Methods 0.000 description 7
- 108091006146 Channels Proteins 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000012267 brine Substances 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- 229910052763 palladium Inorganic materials 0.000 description 6
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
- 230000009182 swimming Effects 0.000 description 6
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 5
- 206010012812 Diffuse cutaneous mastocytosis Diseases 0.000 description 5
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 125000003118 aryl group Chemical group 0.000 description 5
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 5
- 125000005843 halogen group Chemical group 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- NIPVYFDEJFFCLH-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]-3-[3-hydroxy-4-(4-hydroxyphenyl)piperidin-1-yl]pyrrolidin-2-one Chemical compound FC1=CC=C(CN2C(C(CC2)N2CC(C(CC2)C2=CC=C(C=C2)O)O)=O)C=C1 NIPVYFDEJFFCLH-UHFFFAOYSA-N 0.000 description 4
- VADKRMSMGWJZCF-UHFFFAOYSA-N 2-bromophenol Chemical compound OC1=CC=CC=C1Br VADKRMSMGWJZCF-UHFFFAOYSA-N 0.000 description 4
- GXCCYLLPBRUNGP-UHFFFAOYSA-N 4-(3,3-difluoropiperidin-4-yl)phenol Chemical compound FC1(CNCCC1C1=CC=C(C=C1)O)F GXCCYLLPBRUNGP-UHFFFAOYSA-N 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 239000000935 antidepressant agent Substances 0.000 description 4
- 229940005513 antidepressants Drugs 0.000 description 4
- 125000002619 bicyclic group Chemical group 0.000 description 4
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 4
- 239000012467 final product Substances 0.000 description 4
- 238000003818 flash chromatography Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- LKPFBGKZCCBZDK-UHFFFAOYSA-N n-hydroxypiperidine Chemical compound ON1CCCCC1 LKPFBGKZCCBZDK-UHFFFAOYSA-N 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 235000011152 sodium sulphate Nutrition 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- BROWSDUVKNBAHK-RBUKOAKNSA-N (3S,4S)-1-benzyl-4-(4-methoxyphenyl)piperidin-3-ol Chemical compound C(C1=CC=CC=C1)N1C[C@H]([C@@H](CC1)C1=CC=C(C=C1)OC)O BROWSDUVKNBAHK-RBUKOAKNSA-N 0.000 description 3
- NQXYVDTXOJUWOR-NWDGAFQWSA-N (3S,4S)-4-(4-methoxyphenyl)piperidin-3-ol Chemical compound COC1=CC=C(C=C1)[C@H]1[C@@H](CNCC1)O NQXYVDTXOJUWOR-NWDGAFQWSA-N 0.000 description 3
- CNIBEWABPVGSSN-UHFFFAOYSA-N 1-benzyl-3-(4-methoxyphenyl)piperidin-3-ol Chemical compound C1=CC(OC)=CC=C1C1(O)CN(CC=2C=CC=CC=2)CCC1 CNIBEWABPVGSSN-UHFFFAOYSA-N 0.000 description 3
- GROLLLDBWQWNOQ-UHFFFAOYSA-N 1-benzyl-5-(4-methoxyphenyl)-3,6-dihydro-2h-pyridine Chemical compound C1=CC(OC)=CC=C1C(C1)=CCCN1CC1=CC=CC=C1 GROLLLDBWQWNOQ-UHFFFAOYSA-N 0.000 description 3
- VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical compound C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 description 3
- JBMISQBTERXMTI-UHFFFAOYSA-N 3-(4-methoxyphenyl)azetidine Chemical compound C1=CC(OC)=CC=C1C1CNC1 JBMISQBTERXMTI-UHFFFAOYSA-N 0.000 description 3
- XOFIBRNSGSEFHC-UHFFFAOYSA-N 3-(4-methoxyphenyl)piperidine Chemical compound C1=CC(OC)=CC=C1C1CNCCC1 XOFIBRNSGSEFHC-UHFFFAOYSA-N 0.000 description 3
- JSUQBIWIGXMWOW-UHFFFAOYSA-N 5-(4-methoxyphenyl)-2,3,4,7-tetrahydro-1H-azepine hydrochloride Chemical compound Cl.COC1=CC=C(C=C1)C=1CCCNCC1 JSUQBIWIGXMWOW-UHFFFAOYSA-N 0.000 description 3
- WFMKSKBDDGOEEE-UHFFFAOYSA-N 6-(4-methoxyphenyl)-2,3,4,5-tetrahydro-1H-azepine hydrochloride Chemical compound Cl.COC1=CC=C(C=C1)C=1CCCCNC1 WFMKSKBDDGOEEE-UHFFFAOYSA-N 0.000 description 3
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 3
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 3
- 102000004310 Ion Channels Human genes 0.000 description 3
- 108090000862 Ion Channels Proteins 0.000 description 3
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 3
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 3
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 3
- 230000001430 anti-depressive effect Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 125000006310 cycloalkyl amino group Chemical group 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- HJUFTIJOISQSKQ-UHFFFAOYSA-N fenoxycarb Chemical compound C1=CC(OCCNC(=O)OCC)=CC=C1OC1=CC=CC=C1 HJUFTIJOISQSKQ-UHFFFAOYSA-N 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 238000000265 homogenisation Methods 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 229960003299 ketamine Drugs 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 229960003742 phenol Drugs 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 2
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 2
- OIMXBHXLIVXEEQ-GFOWMXPYSA-N (3R)-1-[(4-chlorophenyl)methyl]-3-[3,3-difluoro-4-(4-hydroxyphenyl)piperidin-1-yl]pyrrolidin-2-one Chemical compound ClC1=CC=C(CN2C([C@@H](CC2)N2CC(C(CC2)C2=CC=C(C=C2)O)(F)F)=O)C=C1 OIMXBHXLIVXEEQ-GFOWMXPYSA-N 0.000 description 2
- OIMXBHXLIVXEEQ-ANYOKISRSA-N (3S)-1-[(4-chlorophenyl)methyl]-3-[3,3-difluoro-4-(4-hydroxyphenyl)piperidin-1-yl]pyrrolidin-2-one Chemical compound ClC1=CC=C(CN2C([C@H](CC2)N2CC(C(CC2)C2=CC=C(C=C2)O)(F)F)=O)C=C1 OIMXBHXLIVXEEQ-ANYOKISRSA-N 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- CLNCTPCQWVHYIL-UHFFFAOYSA-N 1-[(3,4-dichlorophenyl)methyl]-3-[3,3-difluoro-4-(4-hydroxyphenyl)piperidin-1-yl]pyrrolidin-2-one Chemical compound ClC=1C=C(CN2C(C(CC2)N2CC(C(CC2)C2=CC=C(C=C2)O)(F)F)=O)C=CC1Cl CLNCTPCQWVHYIL-UHFFFAOYSA-N 0.000 description 2
- VIWNTDGHOMVIMW-UHFFFAOYSA-N 1-[(3-chloro-4-fluorophenyl)methyl]-3-[3,3-difluoro-4-(4-hydroxyphenyl)piperidin-1-yl]pyrrolidin-2-one Chemical compound ClC=1C=C(CN2C(C(CC2)N2CC(C(CC2)C2=CC=C(C=C2)O)(F)F)=O)C=CC1F VIWNTDGHOMVIMW-UHFFFAOYSA-N 0.000 description 2
- OIMXBHXLIVXEEQ-UHFFFAOYSA-N 1-[(4-chlorophenyl)methyl]-3-[3,3-difluoro-4-(4-hydroxyphenyl)piperidin-1-yl]pyrrolidin-2-one Chemical compound OC1=CC=C(C=C1)C1CCN(CC1(F)F)C1CCN(CC2=CC=C(Cl)C=C2)C1=O OIMXBHXLIVXEEQ-UHFFFAOYSA-N 0.000 description 2
- KOQYBHVHTCKDIZ-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]-3-[4-(4-hydroxyphenyl)piperidin-1-yl]pyrrolidin-2-one Chemical compound FC1=CC=C(CN2C(C(CC2)N2CCC(CC2)C2=CC=C(C=C2)O)=O)C=C1 KOQYBHVHTCKDIZ-UHFFFAOYSA-N 0.000 description 2
- OXOBQHYWNDWKCP-UHFFFAOYSA-N 1-benzyl-3-[3,3-difluoro-4-(4-hydroxyphenyl)piperidin-1-yl]pyrrolidin-2-one Chemical compound C(C1=CC=CC=C1)N1C(C(CC1)N1CC(C(CC1)C1=CC=C(C=C1)O)(F)F)=O OXOBQHYWNDWKCP-UHFFFAOYSA-N 0.000 description 2
- ZEUFQXOLSLZULG-UHFFFAOYSA-N 1-benzyl-3-[3-(4-methoxyphenyl)piperidin-1-yl]pyrrolidin-2-one Chemical compound C(C1=CC=CC=C1)N1C(C(CC1)N1CC(CCC1)C1=CC=C(C=C1)OC)=O ZEUFQXOLSLZULG-UHFFFAOYSA-N 0.000 description 2
- UOKUOJQWGPYRIN-UHFFFAOYSA-N 1-benzyl-3-[4-(4-methoxyphenyl)piperidin-1-yl]pyrrolidin-2-one Chemical compound C(C1=CC=CC=C1)N1C(C(CC1)N1CCC(CC1)C1=CC=C(C=C1)OC)=O UOKUOJQWGPYRIN-UHFFFAOYSA-N 0.000 description 2
- OASXCKSPMWTYKM-UHFFFAOYSA-N 1-benzyl-3-bromopiperidin-2-one Chemical compound O=C1C(Br)CCCN1CC1=CC=CC=C1 OASXCKSPMWTYKM-UHFFFAOYSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- XXMFJKNOJSDQBM-UHFFFAOYSA-N 2,2,2-trifluoroacetic acid;hydrate Chemical compound [OH3+].[O-]C(=O)C(F)(F)F XXMFJKNOJSDQBM-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- UOGQPXQDNUHUIB-UHFFFAOYSA-N 3,3-difluoropiperidine Chemical compound FC1(F)CCCNC1 UOGQPXQDNUHUIB-UHFFFAOYSA-N 0.000 description 2
- 125000006509 3,4-difluorobenzyl group Chemical group [H]C1=C(F)C(F)=C([H])C(=C1[H])C([H])([H])* 0.000 description 2
- KUVFQBCWWCBTFO-UHFFFAOYSA-N 3-[3,3-difluoro-4-(4-hydroxyphenyl)piperidin-1-yl]-1-[(2-methylphenyl)methyl]pyrrolidin-2-one Chemical compound FC1(CN(CCC1C1=CC=C(C=C1)O)C1C(N(CC1)CC1=C(C=CC=C1)C)=O)F KUVFQBCWWCBTFO-UHFFFAOYSA-N 0.000 description 2
- VLIVVRVETMYTHW-UHFFFAOYSA-N 3-[3,3-difluoro-4-(4-hydroxyphenyl)piperidin-1-yl]-1-[(3,4-difluorophenyl)methyl]pyrrolidin-2-one Chemical compound FC1(CN(CCC1C1=CC=C(C=C1)O)C1C(N(CC1)CC1=CC(=C(C=C1)F)F)=O)F VLIVVRVETMYTHW-UHFFFAOYSA-N 0.000 description 2
- FEAAPOLQVVDUPG-UHFFFAOYSA-N 3-[3,3-difluoro-4-(4-hydroxyphenyl)piperidin-1-yl]-1-[(3-methylphenyl)methyl]pyrrolidin-2-one Chemical compound FC1(CN(CCC1C1=CC=C(C=C1)O)C1C(N(CC1)CC1=CC(=CC=C1)C)=O)F FEAAPOLQVVDUPG-UHFFFAOYSA-N 0.000 description 2
- RTDKQGYWDLVPDB-UHFFFAOYSA-N 3-[3,3-difluoro-4-(4-hydroxyphenyl)piperidin-1-yl]-1-[[4-(difluoromethoxy)phenyl]methyl]pyrrolidin-2-one Chemical compound FC1(CN(CCC1C1=CC=C(C=C1)O)C1C(N(CC1)CC1=CC=C(C=C1)OC(F)F)=O)F RTDKQGYWDLVPDB-UHFFFAOYSA-N 0.000 description 2
- SVPPSJNIPGZMHE-UHFFFAOYSA-N 3-[3,3-difluoro-4-(4-hydroxyphenyl)piperidin-1-yl]-1-[[4-(trifluoromethyl)phenyl]methyl]pyrrolidin-2-one Chemical compound FC1(CN(CCC1C1=CC=C(C=C1)O)C1C(N(CC1)CC1=CC=C(C=C1)C(F)(F)F)=O)F SVPPSJNIPGZMHE-UHFFFAOYSA-N 0.000 description 2
- YUKQZLBLVRAJSW-UHFFFAOYSA-N 3-fluoropiperidine Chemical compound FC1CCCNC1 YUKQZLBLVRAJSW-UHFFFAOYSA-N 0.000 description 2
- REHFBEFMGKEPIU-UHFFFAOYSA-N 4-(4-methoxyphenyl)-1,2,3,6-tetrahydropyridine;hydrochloride Chemical compound Cl.C1=CC(OC)=CC=C1C1=CCNCC1 REHFBEFMGKEPIU-UHFFFAOYSA-N 0.000 description 2
- GTHXQDYBGATGPF-UHFFFAOYSA-N 4-(4-methoxyphenyl)piperidine;hydrochloride Chemical compound Cl.C1=CC(OC)=CC=C1C1CCNCC1 GTHXQDYBGATGPF-UHFFFAOYSA-N 0.000 description 2
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 2
- QJPJQTDYNZXKQF-UHFFFAOYSA-N 4-bromoanisole Chemical compound COC1=CC=C(Br)C=C1 QJPJQTDYNZXKQF-UHFFFAOYSA-N 0.000 description 2
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 description 2
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 description 2
- KQKFQBTWXOGINC-UHFFFAOYSA-N 4-phenylpiperidin-4-ol Chemical compound C=1C=CC=CC=1C1(O)CCNCC1 KQKFQBTWXOGINC-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 229940126657 Compound 17 Drugs 0.000 description 2
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 239000005909 Kieselgur Substances 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 102000014649 NMDA glutamate receptor activity proteins Human genes 0.000 description 2
- 102000038100 NR2 subfamily Human genes 0.000 description 2
- 108020002076 NR2 subfamily Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 150000001263 acyl chlorides Chemical class 0.000 description 2
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 210000003050 axon Anatomy 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229940125797 compound 12 Drugs 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Substances CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000007667 floating Methods 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 210000004129 prosencephalon Anatomy 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000002287 radioligand Substances 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- FTNBYFFAMAJVML-UHFFFAOYSA-N tert-butyl 4-hydroxy-4-(4-methoxyphenyl)piperidine-1-carboxylate Chemical compound C1=CC(OC)=CC=C1C1(O)CCN(C(=O)OC(C)(C)C)CC1 FTNBYFFAMAJVML-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 2
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 2
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 2
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 2
- BSVHTRRLCAVQCZ-JDEXMCKMSA-N (2s)-1-[(2s)-1-[(2s)-1-[(2s)-1-[(2s)-1-[(2s)-1-[(2s)-2-[[(2s)-1-[(2s)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-carboxypropanoyl]pyrrolidine-2-carbonyl]amino]propanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]pyrro Chemical compound C([C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(O)=O)C1=CC=C(O)C=C1 BSVHTRRLCAVQCZ-JDEXMCKMSA-N 0.000 description 1
- XCAJNBJDLZPHNB-UHFFFAOYSA-N (3-fluoro-4-methylphenyl)methanamine Chemical compound CC1=CC=C(CN)C=C1F XCAJNBJDLZPHNB-UHFFFAOYSA-N 0.000 description 1
- ONAABSNIFZNNAW-OAQYLSRUSA-N (3R)-1-[(3,4-difluorophenyl)methyl]-3-[4-(4-hydroxyphenyl)piperidin-1-yl]pyrrolidin-2-one Chemical compound FC=1C=C(CN2C([C@@H](CC2)N2CCC(CC2)C2=CC=C(C=C2)O)=O)C=CC1F ONAABSNIFZNNAW-OAQYLSRUSA-N 0.000 description 1
- IXTMSISYSYXUJS-LJQANCHMSA-N (3R)-1-[(3,4-dihydroxyphenyl)methyl]-3-[4-(4-hydroxyphenyl)piperidin-1-yl]pyrrolidin-2-one Chemical compound OC=1C=C(CN2C([C@@H](CC2)N2CCC(CC2)C2=CC=C(C=C2)O)=O)C=CC1O IXTMSISYSYXUJS-LJQANCHMSA-N 0.000 description 1
- IESUXIJJIRXKNX-HXUWFJFHSA-N (3R)-1-[(3-fluoro-4-methylphenyl)methyl]-3-[3-(4-hydroxyphenyl)azetidin-1-yl]pyrrolidin-2-one Chemical compound FC=1C=C(CN2C([C@@H](CC2)N2CC(C2)C2=CC=C(C=C2)O)=O)C=CC1C IESUXIJJIRXKNX-HXUWFJFHSA-N 0.000 description 1
- JATJVTHLUABLLD-JRGCBEDISA-N (3R)-1-[(4-chloro-3-fluorophenyl)methyl]-3-[(3R,4R)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl]pyrrolidin-2-one Chemical compound ClC1=C(C=C(CN2C([C@@H](CC2)N2C[C@@H]([C@H](CC2)C2=CC=C(C=C2)O)F)=O)C=C1)F JATJVTHLUABLLD-JRGCBEDISA-N 0.000 description 1
- JATJVTHLUABLLD-IOMROCGXSA-N (3R)-1-[(4-chloro-3-fluorophenyl)methyl]-3-[(3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl]pyrrolidin-2-one Chemical compound ClC1=C(C=C(CN2C([C@@H](CC2)N2C[C@H]([C@@H](CC2)C2=CC=C(C=C2)O)F)=O)C=C1)F JATJVTHLUABLLD-IOMROCGXSA-N 0.000 description 1
- WMDFOUUNXWEBFQ-QHAWAJNXSA-N (3R)-1-[(4-chlorophenyl)methyl]-3-[(3R,4R)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl]pyrrolidin-2-one Chemical compound ClC1=CC=C(CN2C([C@@H](CC2)N2C[C@@H]([C@H](CC2)C2=CC=C(C=C2)O)F)=O)C=C1 WMDFOUUNXWEBFQ-QHAWAJNXSA-N 0.000 description 1
- WMDFOUUNXWEBFQ-PWRODBHTSA-N (3R)-1-[(4-chlorophenyl)methyl]-3-[(3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl]pyrrolidin-2-one Chemical compound ClC1=CC=C(CN2C([C@@H](CC2)N2C[C@H]([C@@H](CC2)C2=CC=C(C=C2)O)F)=O)C=C1 WMDFOUUNXWEBFQ-PWRODBHTSA-N 0.000 description 1
- PNRRDRBTZYBOHX-OAQYLSRUSA-N (3R)-1-[(4-chlorophenyl)methyl]-3-[4-(4-hydroxyphenyl)piperidin-1-yl]pyrrolidin-2-one Chemical compound ClC1=CC=C(CN2C([C@@H](CC2)N2CCC(CC2)C2=CC=C(C=C2)O)=O)C=C1 PNRRDRBTZYBOHX-OAQYLSRUSA-N 0.000 description 1
- KOQYBHVHTCKDIZ-OAQYLSRUSA-N (3R)-1-[(4-fluorophenyl)methyl]-3-[4-(4-hydroxyphenyl)piperidin-1-yl]pyrrolidin-2-one Chemical compound FC1=CC=C(CN2C([C@@H](CC2)N2CCC(CC2)C2=CC=C(C=C2)O)=O)C=C1 KOQYBHVHTCKDIZ-OAQYLSRUSA-N 0.000 description 1
- HEZHOLUAZMQEBN-OAQYLSRUSA-N (3R)-1-[(4-hydroxyphenyl)methyl]-3-[4-(4-hydroxyphenyl)piperidin-1-yl]pyrrolidin-2-one Chemical compound OC1=CC=C(CN2C([C@@H](CC2)N2CCC(CC2)C2=CC=C(C=C2)O)=O)C=C1 HEZHOLUAZMQEBN-OAQYLSRUSA-N 0.000 description 1
- QGVLIVYFBAIXBS-DFQSSKMNSA-N (3R)-1-[[4-(difluoromethyl)phenyl]methyl]-3-[(3S,4S)-3-fluoro-4-(3-fluoro-4-hydroxyphenyl)piperidin-1-yl]pyrrolidin-2-one Chemical compound FC(C1=CC=C(CN2C([C@@H](CC2)N2C[C@H]([C@@H](CC2)C2=CC(=C(C=C2)O)F)F)=O)C=C1)F QGVLIVYFBAIXBS-DFQSSKMNSA-N 0.000 description 1
- SESJORIIMPHFEV-QHAWAJNXSA-N (3R)-1-benzyl-3-[(3R,4R)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl]pyrrolidin-2-one Chemical compound C(C1=CC=CC=C1)N1C([C@@H](CC1)N1C[C@@H]([C@H](CC1)C1=CC=C(C=C1)O)F)=O SESJORIIMPHFEV-QHAWAJNXSA-N 0.000 description 1
- SESJORIIMPHFEV-PWRODBHTSA-N (3R)-1-benzyl-3-[(3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl]pyrrolidin-2-one Chemical compound C(C1=CC=CC=C1)N1C([C@@H](CC1)N1C[C@H]([C@@H](CC1)C1=CC=C(C=C1)O)F)=O SESJORIIMPHFEV-PWRODBHTSA-N 0.000 description 1
- OXOBQHYWNDWKCP-GFOWMXPYSA-N (3R)-1-benzyl-3-[3,3-difluoro-4-(4-hydroxyphenyl)piperidin-1-yl]pyrrolidin-2-one Chemical compound C(C1=CC=CC=C1)N1C([C@@H](CC1)N1CC(C(CC1)C1=CC=C(C=C1)O)(F)F)=O OXOBQHYWNDWKCP-GFOWMXPYSA-N 0.000 description 1
- PHBBGHAXNTZALA-OAQYLSRUSA-N (3R)-1-benzyl-3-[4-(4-hydroxyphenyl)piperidin-1-yl]pyrrolidin-2-one Chemical compound C(C1=CC=CC=C1)N1C([C@@H](CC1)N1CCC(CC1)C1=CC=C(C=C1)O)=O PHBBGHAXNTZALA-OAQYLSRUSA-N 0.000 description 1
- XLERPYDVNGAEHV-QWIYEXKTSA-N (3R)-3-[(3R,4R)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl]-1-[(1S)-1-(4-fluorophenyl)ethyl]pyrrolidin-2-one Chemical compound F[C@H]1CN(CC[C@@H]1C1=CC=C(C=C1)O)[C@H]1C(N(CC1)[C@@H](C)C1=CC=C(C=C1)F)=O XLERPYDVNGAEHV-QWIYEXKTSA-N 0.000 description 1
- YALQZTSLSZMJHO-QHAWAJNXSA-N (3R)-3-[(3R,4R)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl]-1-[[4-(trifluoromethyl)phenyl]methyl]pyrrolidin-2-one Chemical compound F[C@H]1CN(CC[C@@H]1C1=CC=C(C=C1)O)[C@H]1C(N(CC1)CC1=CC=C(C=C1)C(F)(F)F)=O YALQZTSLSZMJHO-QHAWAJNXSA-N 0.000 description 1
- UNVYDSCXINFREZ-FDFHNCONSA-N (3R)-3-[(3R,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl]-1-[(4-methylphenyl)methyl]pyrrolidin-2-one Chemical compound F[C@H]1CN(CC[C@H]1C1=CC=C(C=C1)O)[C@H]1C(N(CC1)CC1=CC=C(C=C1)C)=O UNVYDSCXINFREZ-FDFHNCONSA-N 0.000 description 1
- UNVYDSCXINFREZ-YPAWHYETSA-N (3R)-3-[(3S,4R)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl]-1-[(4-methylphenyl)methyl]pyrrolidin-2-one Chemical compound F[C@@H]1CN(CC[C@@H]1C1=CC=C(C=C1)O)[C@H]1C(N(CC1)CC1=CC=C(C=C1)C)=O UNVYDSCXINFREZ-YPAWHYETSA-N 0.000 description 1
- XLERPYDVNGAEHV-DSAKXZLESA-N (3R)-3-[(3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl]-1-[(1S)-1-(4-fluorophenyl)ethyl]pyrrolidin-2-one Chemical compound F[C@@H]1CN(CC[C@H]1C1=CC=C(C=C1)O)[C@H]1C(N(CC1)[C@@H](C)C1=CC=C(C=C1)F)=O XLERPYDVNGAEHV-DSAKXZLESA-N 0.000 description 1
- YALQZTSLSZMJHO-PWRODBHTSA-N (3R)-3-[(3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl]-1-[[4-(trifluoromethyl)phenyl]methyl]pyrrolidin-2-one Chemical compound F[C@@H]1CN(CC[C@H]1C1=CC=C(C=C1)O)[C@H]1C(N(CC1)CC1=CC=C(C=C1)C(F)(F)F)=O YALQZTSLSZMJHO-PWRODBHTSA-N 0.000 description 1
- VORAXNUWZGHPKU-IWMITWMQSA-N (3R)-3-[(4R)-3,3-difluoro-4-(4-hydroxyphenyl)piperidin-1-yl]-1-[(1S)-1-(4-fluorophenyl)ethyl]pyrrolidin-2-one Chemical compound FC1(CN(CC[C@@H]1C1=CC=C(C=C1)O)[C@H]1C(N(CC1)[C@@H](C)C1=CC=C(C=C1)F)=O)F VORAXNUWZGHPKU-IWMITWMQSA-N 0.000 description 1
- VORAXNUWZGHPKU-ONGXBYRLSA-N (3R)-3-[(4S)-3,3-difluoro-4-(4-hydroxyphenyl)piperidin-1-yl]-1-[(1S)-1-(4-fluorophenyl)ethyl]pyrrolidin-2-one Chemical compound FC1(CN(CC[C@H]1C1=CC=C(C=C1)O)[C@H]1C(N(CC1)[C@@H](C)C1=CC=C(C=C1)F)=O)F VORAXNUWZGHPKU-ONGXBYRLSA-N 0.000 description 1
- QBTBTOLRDHNEQE-HXUWFJFHSA-N (3R)-3-[3-(4-hydroxyphenyl)azetidin-1-yl]-1-[(4-methylphenyl)methyl]pyrrolidin-2-one Chemical compound OC1=CC=C(C=C1)C1CN(C1)[C@H]1C(N(CC1)CC1=CC=C(C=C1)C)=O QBTBTOLRDHNEQE-HXUWFJFHSA-N 0.000 description 1
- WKOQGHBYQWAKIH-HTAPYJJXSA-N (3R)-3-[4-(4-hydroxyphenyl)piperidin-1-yl]-1-[(1S)-1-phenylethyl]pyrrolidin-2-one Chemical compound OC1=CC=C(C=C1)C1CCN(CC1)[C@H]1C(N(CC1)[C@@H](C)C1=CC=CC=C1)=O WKOQGHBYQWAKIH-HTAPYJJXSA-N 0.000 description 1
- ILUHFPBBZNEUNW-JOCHJYFZSA-N (3R)-3-[4-(4-hydroxyphenyl)piperidin-1-yl]-1-[(4-methylphenyl)methyl]pyrrolidin-2-one Chemical compound OC1=CC=C(C=C1)C1CCN(CC1)[C@H]1C(N(CC1)CC1=CC=C(C=C1)C)=O ILUHFPBBZNEUNW-JOCHJYFZSA-N 0.000 description 1
- ONAABSNIFZNNAW-NRFANRHFSA-N (3S)-1-[(3,4-difluorophenyl)methyl]-3-[4-(4-hydroxyphenyl)piperidin-1-yl]pyrrolidin-2-one Chemical compound FC=1C=C(CN2C([C@H](CC2)N2CCC(CC2)C2=CC=C(C=C2)O)=O)C=CC1F ONAABSNIFZNNAW-NRFANRHFSA-N 0.000 description 1
- IESUXIJJIRXKNX-FQEVSTJZSA-N (3S)-1-[(3-fluoro-4-methylphenyl)methyl]-3-[3-(4-hydroxyphenyl)azetidin-1-yl]pyrrolidin-2-one Chemical compound FC=1C=C(CN2C([C@H](CC2)N2CC(C2)C2=CC=C(C=C2)O)=O)C=CC1C IESUXIJJIRXKNX-FQEVSTJZSA-N 0.000 description 1
- JATJVTHLUABLLD-QMMLZNLJSA-N (3S)-1-[(4-chloro-3-fluorophenyl)methyl]-3-[(3R,4R)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl]pyrrolidin-2-one Chemical compound ClC1=C(C=C(CN2C([C@H](CC2)N2C[C@@H]([C@H](CC2)C2=CC=C(C=C2)O)F)=O)C=C1)F JATJVTHLUABLLD-QMMLZNLJSA-N 0.000 description 1
- JATJVTHLUABLLD-WMQCIHAUSA-N (3S)-1-[(4-chloro-3-fluorophenyl)methyl]-3-[(3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl]pyrrolidin-2-one Chemical compound ClC1=C(C=C(CN2C([C@H](CC2)N2C[C@H]([C@@H](CC2)C2=CC=C(C=C2)O)F)=O)C=C1)F JATJVTHLUABLLD-WMQCIHAUSA-N 0.000 description 1
- WMDFOUUNXWEBFQ-HKBOAZHASA-N (3S)-1-[(4-chlorophenyl)methyl]-3-[(3R,4R)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl]pyrrolidin-2-one Chemical compound ClC1=CC=C(CN2C([C@H](CC2)N2C[C@@H]([C@H](CC2)C2=CC=C(C=C2)O)F)=O)C=C1 WMDFOUUNXWEBFQ-HKBOAZHASA-N 0.000 description 1
- WMDFOUUNXWEBFQ-HBMCJLEFSA-N (3S)-1-[(4-chlorophenyl)methyl]-3-[(3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl]pyrrolidin-2-one Chemical compound ClC1=CC=C(CN2C([C@H](CC2)N2C[C@H]([C@@H](CC2)C2=CC=C(C=C2)O)F)=O)C=C1 WMDFOUUNXWEBFQ-HBMCJLEFSA-N 0.000 description 1
- PNRRDRBTZYBOHX-NRFANRHFSA-N (3S)-1-[(4-chlorophenyl)methyl]-3-[4-(4-hydroxyphenyl)piperidin-1-yl]pyrrolidin-2-one Chemical compound ClC1=CC=C(CN2C([C@H](CC2)N2CCC(CC2)C2=CC=C(C=C2)O)=O)C=C1 PNRRDRBTZYBOHX-NRFANRHFSA-N 0.000 description 1
- KOQYBHVHTCKDIZ-NRFANRHFSA-N (3S)-1-[(4-fluorophenyl)methyl]-3-[4-(4-hydroxyphenyl)piperidin-1-yl]pyrrolidin-2-one Chemical compound FC1=CC=C(CN2C([C@H](CC2)N2CCC(CC2)C2=CC=C(C=C2)O)=O)C=C1 KOQYBHVHTCKDIZ-NRFANRHFSA-N 0.000 description 1
- HEZHOLUAZMQEBN-NRFANRHFSA-N (3S)-1-[(4-hydroxyphenyl)methyl]-3-[4-(4-hydroxyphenyl)piperidin-1-yl]pyrrolidin-2-one Chemical compound OC1=CC=C(CN2C([C@H](CC2)N2CCC(CC2)C2=CC=C(C=C2)O)=O)C=C1 HEZHOLUAZMQEBN-NRFANRHFSA-N 0.000 description 1
- QGVLIVYFBAIXBS-SXLOBPIMSA-N (3S)-1-[[4-(difluoromethyl)phenyl]methyl]-3-[(3S,4S)-3-fluoro-4-(3-fluoro-4-hydroxyphenyl)piperidin-1-yl]pyrrolidin-2-one Chemical compound FC(C1=CC=C(CN2C([C@H](CC2)N2C[C@H]([C@@H](CC2)C2=CC(=C(C=C2)O)F)F)=O)C=C1)F QGVLIVYFBAIXBS-SXLOBPIMSA-N 0.000 description 1
- SESJORIIMPHFEV-HKBOAZHASA-N (3S)-1-benzyl-3-[(3R,4R)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl]pyrrolidin-2-one Chemical compound C(C1=CC=CC=C1)N1C([C@H](CC1)N1C[C@@H]([C@H](CC1)C1=CC=C(C=C1)O)F)=O SESJORIIMPHFEV-HKBOAZHASA-N 0.000 description 1
- SESJORIIMPHFEV-HBMCJLEFSA-N (3S)-1-benzyl-3-[(3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl]pyrrolidin-2-one Chemical compound C(C1=CC=CC=C1)N1C([C@H](CC1)N1C[C@H]([C@@H](CC1)C1=CC=C(C=C1)O)F)=O SESJORIIMPHFEV-HBMCJLEFSA-N 0.000 description 1
- OXOBQHYWNDWKCP-ANYOKISRSA-N (3S)-1-benzyl-3-[3,3-difluoro-4-(4-hydroxyphenyl)piperidin-1-yl]pyrrolidin-2-one Chemical compound C(C1=CC=CC=C1)N1C([C@H](CC1)N1CC(C(CC1)C1=CC=C(C=C1)O)(F)F)=O OXOBQHYWNDWKCP-ANYOKISRSA-N 0.000 description 1
- PHBBGHAXNTZALA-NRFANRHFSA-N (3S)-1-benzyl-3-[4-(4-hydroxyphenyl)piperidin-1-yl]pyrrolidin-2-one Chemical compound C(C1=CC=CC=C1)N1C([C@H](CC1)N1CCC(CC1)C1=CC=C(C=C1)O)=O PHBBGHAXNTZALA-NRFANRHFSA-N 0.000 description 1
- XLERPYDVNGAEHV-NZYDNVMFSA-N (3S)-3-[(3R,4R)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl]-1-[(1S)-1-(4-fluorophenyl)ethyl]pyrrolidin-2-one Chemical compound F[C@H]1CN(CC[C@@H]1C1=CC=C(C=C1)O)[C@@H]1C(N(CC1)[C@@H](C)C1=CC=C(C=C1)F)=O XLERPYDVNGAEHV-NZYDNVMFSA-N 0.000 description 1
- YALQZTSLSZMJHO-HKBOAZHASA-N (3S)-3-[(3R,4R)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl]-1-[[4-(trifluoromethyl)phenyl]methyl]pyrrolidin-2-one Chemical compound F[C@H]1CN(CC[C@@H]1C1=CC=C(C=C1)O)[C@@H]1C(N(CC1)CC1=CC=C(C=C1)C(F)(F)F)=O YALQZTSLSZMJHO-HKBOAZHASA-N 0.000 description 1
- XLERPYDVNGAEHV-RWXMBLCBSA-N (3S)-3-[(3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl]-1-[(1S)-1-(4-fluorophenyl)ethyl]pyrrolidin-2-one Chemical compound F[C@@H]1CN(CC[C@H]1C1=CC=C(C=C1)O)[C@@H]1C(N(CC1)[C@@H](C)C1=CC=C(C=C1)F)=O XLERPYDVNGAEHV-RWXMBLCBSA-N 0.000 description 1
- YALQZTSLSZMJHO-HBMCJLEFSA-N (3S)-3-[(3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl]-1-[[4-(trifluoromethyl)phenyl]methyl]pyrrolidin-2-one Chemical compound F[C@@H]1CN(CC[C@H]1C1=CC=C(C=C1)O)[C@@H]1C(N(CC1)CC1=CC=C(C=C1)C(F)(F)F)=O YALQZTSLSZMJHO-HBMCJLEFSA-N 0.000 description 1
- RUJFBNIDDSNLJQ-ICSRJNTNSA-N (3S)-3-[(4S)-3,3-difluoro-4-(4-hydroxyphenyl)piperidin-1-yl]-1-(3-fluoro-4-methylphenyl)pyrrolidin-2-one Chemical compound FC1(CN(CC[C@H]1C1=CC=C(C=C1)O)[C@@H]1C(N(CC1)C1=CC(=C(C=C1)C)F)=O)F RUJFBNIDDSNLJQ-ICSRJNTNSA-N 0.000 description 1
- VORAXNUWZGHPKU-JHVJFLLYSA-N (3S)-3-[(4S)-3,3-difluoro-4-(4-hydroxyphenyl)piperidin-1-yl]-1-[(1S)-1-(4-fluorophenyl)ethyl]pyrrolidin-2-one Chemical compound FC1(CN(CC[C@H]1C1=CC=C(C=C1)O)[C@@H]1C(N(CC1)[C@@H](C)C1=CC=C(C=C1)F)=O)F VORAXNUWZGHPKU-JHVJFLLYSA-N 0.000 description 1
- WKOQGHBYQWAKIH-JTSKRJEESA-N (3S)-3-[4-(4-hydroxyphenyl)piperidin-1-yl]-1-[(1S)-1-phenylethyl]pyrrolidin-2-one Chemical compound OC1=CC=C(C=C1)C1CCN(CC1)[C@@H]1C(N(CC1)[C@@H](C)C1=CC=CC=C1)=O WKOQGHBYQWAKIH-JTSKRJEESA-N 0.000 description 1
- ILUHFPBBZNEUNW-QFIPXVFZSA-N (3S)-3-[4-(4-hydroxyphenyl)piperidin-1-yl]-1-[(4-methylphenyl)methyl]pyrrolidin-2-one Chemical compound OC1=CC=C(C=C1)C1CCN(CC1)[C@@H]1C(N(CC1)CC1=CC=C(C=C1)C)=O ILUHFPBBZNEUNW-QFIPXVFZSA-N 0.000 description 1
- QEMSVZNTSXPFJA-HNAYVOBHSA-N 1-[(1s,2s)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]-4-phenylpiperidin-4-ol Chemical compound C1([C@H](O)[C@H](C)N2CCC(O)(CC2)C=2C=CC=CC=2)=CC=C(O)C=C1 QEMSVZNTSXPFJA-HNAYVOBHSA-N 0.000 description 1
- JHGABUJRIZEJET-HXOQZHHGSA-N 1-[(3,4-dichlorophenyl)methyl]-3-[(3R,4R)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl]pyrrolidin-2-one Chemical compound ClC=1C=C(CN2C(C(CC2)N2C[C@@H]([C@H](CC2)C2=CC=C(C=C2)O)F)=O)C=CC1Cl JHGABUJRIZEJET-HXOQZHHGSA-N 0.000 description 1
- JHGABUJRIZEJET-DVUUQMMQSA-N 1-[(3,4-dichlorophenyl)methyl]-3-[(3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl]pyrrolidin-2-one Chemical compound ClC=1C=C(CN2C(C(CC2)N2C[C@H]([C@@H](CC2)C2=CC=C(C=C2)O)F)=O)C=CC1Cl JHGABUJRIZEJET-DVUUQMMQSA-N 0.000 description 1
- GEARHVGBHFRSBG-HXOQZHHGSA-N 1-[(3,4-difluorophenyl)methyl]-3-[(3R,4R)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl]pyrrolidin-2-one Chemical compound FC=1C=C(CN2C(C(CC2)N2C[C@@H]([C@H](CC2)C2=CC=C(C=C2)O)F)=O)C=CC1F GEARHVGBHFRSBG-HXOQZHHGSA-N 0.000 description 1
- GEARHVGBHFRSBG-DVUUQMMQSA-N 1-[(3,4-difluorophenyl)methyl]-3-[(3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl]pyrrolidin-2-one Chemical compound FC=1C=C(CN2C(C(CC2)N2C[C@H]([C@@H](CC2)C2=CC=C(C=C2)O)F)=O)C=CC1F GEARHVGBHFRSBG-DVUUQMMQSA-N 0.000 description 1
- MNXQMDYGFBZPDD-UHFFFAOYSA-N 1-[(3,4-difluorophenyl)methyl]-3-[3-(4-hydroxyphenyl)azetidin-1-yl]pyrrolidin-2-one Chemical compound FC=1C=C(CN2C(C(CC2)N2CC(C2)C2=CC=C(C=C2)O)=O)C=CC1F MNXQMDYGFBZPDD-UHFFFAOYSA-N 0.000 description 1
- ONAABSNIFZNNAW-UHFFFAOYSA-N 1-[(3,4-difluorophenyl)methyl]-3-[4-(4-hydroxyphenyl)piperidin-1-yl]pyrrolidin-2-one Chemical compound FC=1C=C(CN2C(C(CC2)N2CCC(CC2)C2=CC=C(C=C2)O)=O)C=CC1F ONAABSNIFZNNAW-UHFFFAOYSA-N 0.000 description 1
- BGRHMASKGAZXFJ-UHFFFAOYSA-N 1-[(3,4-dimethylphenyl)methyl]-3-[4-(4-hydroxyphenyl)piperidin-1-yl]pyrrolidin-2-one Chemical compound CC=1C=C(CN2C(C(CC2)N2CCC(CC2)C2=CC=C(C=C2)O)=O)C=CC1C BGRHMASKGAZXFJ-UHFFFAOYSA-N 0.000 description 1
- FDBBJNOKPFRGFR-HXOQZHHGSA-N 1-[(3-chloro-4-fluorophenyl)methyl]-3-[(3R,4R)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl]pyrrolidin-2-one Chemical compound ClC=1C=C(CN2C(C(CC2)N2C[C@@H]([C@H](CC2)C2=CC=C(C=C2)O)F)=O)C=CC1F FDBBJNOKPFRGFR-HXOQZHHGSA-N 0.000 description 1
- FDBBJNOKPFRGFR-DVUUQMMQSA-N 1-[(3-chloro-4-fluorophenyl)methyl]-3-[(3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl]pyrrolidin-2-one Chemical compound ClC=1C=C(CN2C(C(CC2)N2C[C@H]([C@@H](CC2)C2=CC=C(C=C2)O)F)=O)C=CC1F FDBBJNOKPFRGFR-DVUUQMMQSA-N 0.000 description 1
- YDYIBWVPPQZWMY-UHFFFAOYSA-N 1-[(3-chloro-4-methylphenyl)methyl]-3-[4-(4-hydroxyphenyl)piperidin-1-yl]pyrrolidin-2-one Chemical compound ClC=1C=C(CN2C(C(CC2)N2CCC(CC2)C2=CC=C(C=C2)O)=O)C=CC1C YDYIBWVPPQZWMY-UHFFFAOYSA-N 0.000 description 1
- IESUXIJJIRXKNX-UHFFFAOYSA-N 1-[(3-fluoro-4-methylphenyl)methyl]-3-[3-(4-hydroxyphenyl)azetidin-1-yl]pyrrolidin-2-one Chemical compound FC=1C=C(CN2C(C(CC2)N2CC(C2)C2=CC=C(C=C2)O)=O)C=CC1C IESUXIJJIRXKNX-UHFFFAOYSA-N 0.000 description 1
- BFNVARBGVYWCQZ-UHFFFAOYSA-N 1-[(3-fluoro-4-methylphenyl)methyl]-3-[4-(4-hydroxyphenyl)piperidin-1-yl]pyrrolidin-2-one Chemical compound FC=1C=C(CN2C(C(CC2)N2CCC(CC2)C2=CC=C(C=C2)O)=O)C=CC1C BFNVARBGVYWCQZ-UHFFFAOYSA-N 0.000 description 1
- DWVPNVCSRAPCCL-UHFFFAOYSA-N 1-[(4-chloro-3-fluorophenyl)methyl]-3-[4-(4-hydroxyphenyl)piperidin-1-yl]pyrrolidin-2-one Chemical compound ClC1=C(C=C(CN2C(C(CC2)N2CCC(CC2)C2=CC=C(C=C2)O)=O)C=C1)F DWVPNVCSRAPCCL-UHFFFAOYSA-N 0.000 description 1
- URBGAGWNXFYVMQ-XRRBNZLQSA-N 1-[(4-chlorophenyl)methyl]-3-[(3S,4S)-3-fluoro-4-(3-fluoro-4-hydroxyphenyl)piperidin-1-yl]pyrrolidin-2-one Chemical compound ClC1=CC=C(CN2C(C(CC2)N2C[C@H]([C@@H](CC2)C2=CC(=C(C=C2)O)F)F)=O)C=C1 URBGAGWNXFYVMQ-XRRBNZLQSA-N 0.000 description 1
- PNRRDRBTZYBOHX-UHFFFAOYSA-N 1-[(4-chlorophenyl)methyl]-3-[4-(4-hydroxyphenyl)piperidin-1-yl]pyrrolidin-2-one Chemical compound ClC1=CC=C(CN2C(C(CC2)N2CCC(CC2)C2=CC=C(C=C2)O)=O)C=C1 PNRRDRBTZYBOHX-UHFFFAOYSA-N 0.000 description 1
- DUBRFRUNLHDROO-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]-3-[3-(4-hydroxyphenyl)azepan-1-yl]pyrrolidin-2-one Chemical compound FC1=CC=C(CN2C(C(CC2)N2CC(CCCC2)C2=CC=C(C=C2)O)=O)C=C1 DUBRFRUNLHDROO-UHFFFAOYSA-N 0.000 description 1
- NSIFFWZAJAEDHZ-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]-3-[3-(4-hydroxyphenyl)azetidin-1-yl]pyrrolidin-2-one Chemical compound FC1=CC=C(CN2C(C(CC2)N2CC(C2)C2=CC=C(C=C2)O)=O)C=C1 NSIFFWZAJAEDHZ-UHFFFAOYSA-N 0.000 description 1
- CVKSVTHKTSNIGJ-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]-3-[3-(4-hydroxyphenyl)piperidin-1-yl]pyrrolidin-2-one Chemical compound FC1=CC=C(CN2C(C(CC2)N2CC(CCC2)C2=CC=C(C=C2)O)=O)C=C1 CVKSVTHKTSNIGJ-UHFFFAOYSA-N 0.000 description 1
- AGAILEHGQCMFBR-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]-3-[4-(4-hydroxyphenyl)azepan-1-yl]pyrrolidin-2-one Chemical compound FC1=CC=C(CN2C(C(CC2)N2CCC(CCC2)C2=CC=C(C=C2)O)=O)C=C1 AGAILEHGQCMFBR-UHFFFAOYSA-N 0.000 description 1
- MDUXGCPBQKKLGB-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]-3-[4-(4-hydroxyphenyl)piperazin-1-yl]pyrrolidin-2-one Chemical compound FC1=CC=C(CN2C(C(CC2)N2CCN(CC2)C2=CC=C(C=C2)O)=O)C=C1 MDUXGCPBQKKLGB-UHFFFAOYSA-N 0.000 description 1
- PAMBPKHUMKXDLA-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]-3-[4-(4-methoxyphenyl)piperidin-1-yl]pyrrolidin-2-one Chemical compound FC1=CC=C(CN2C(C(CC2)N2CCC(CC2)C2=CC=C(C=C2)OC)=O)C=C1 PAMBPKHUMKXDLA-UHFFFAOYSA-N 0.000 description 1
- HEZHOLUAZMQEBN-UHFFFAOYSA-N 1-[(4-hydroxyphenyl)methyl]-3-[4-(4-hydroxyphenyl)piperidin-1-yl]pyrrolidin-2-one Chemical compound OC1=CC=C(CN2C(C(CC2)N2CCC(CC2)C2=CC=C(C=C2)O)=O)C=C1 HEZHOLUAZMQEBN-UHFFFAOYSA-N 0.000 description 1
- ZINNJNWQBUSWGG-FAZYOCGDSA-N 1-[3-chloro-4-(difluoromethoxy)phenyl]-3-[(3R,4R)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl]pyrrolidin-2-one Chemical compound ClC=1C=C(C=CC1OC(F)F)N1C(C(CC1)N1C[C@@H]([C@H](CC1)C1=CC=C(C=C1)O)F)=O ZINNJNWQBUSWGG-FAZYOCGDSA-N 0.000 description 1
- UMACWEJWGGYMLA-UHFFFAOYSA-N 1-[3-chloro-4-(difluoromethoxy)phenyl]-3-[3,3-difluoro-4-(4-hydroxyphenyl)piperidin-1-yl]pyrrolidin-2-one Chemical compound ClC=1C=C(C=CC1OC(F)F)N1C(C(CC1)N1CC(C(CC1)C1=CC=C(C=C1)O)(F)F)=O UMACWEJWGGYMLA-UHFFFAOYSA-N 0.000 description 1
- PNHIUDSSYHTHOT-UHFFFAOYSA-N 1-[[4-(difluoromethoxy)phenyl]methyl]-3-[4-(4-hydroxyphenyl)piperidin-1-yl]pyrrolidin-2-one Chemical compound FC(OC1=CC=C(CN2C(C(CC2)N2CCC(CC2)C2=CC=C(C=C2)O)=O)C=C1)F PNHIUDSSYHTHOT-UHFFFAOYSA-N 0.000 description 1
- BABMNZDYRDDBIT-UHFFFAOYSA-N 1-benzyl-3-[3-(4-hydroxyphenyl)azetidin-1-yl]pyrrolidin-2-one Chemical compound C(C1=CC=CC=C1)N1C(C(CC1)N1CC(C1)C1=CC=C(C=C1)O)=O BABMNZDYRDDBIT-UHFFFAOYSA-N 0.000 description 1
- FGYWBVVJUUWCLN-UHFFFAOYSA-N 1-benzyl-3-[4-(3-fluoro-4-hydroxyphenyl)piperidin-1-yl]pyrrolidin-2-one Chemical compound C(C1=CC=CC=C1)N1C(C(CC1)N1CCC(CC1)C1=CC(=C(C=C1)O)F)=O FGYWBVVJUUWCLN-UHFFFAOYSA-N 0.000 description 1
- JOFOAGSZQAGZDV-UHFFFAOYSA-N 1-benzyl-3-[4-(4-hydroxy-2-methylphenyl)piperidin-1-yl]pyrrolidin-2-one Chemical compound C(C1=CC=CC=C1)N1C(C(CC1)N1CCC(CC1)C1=C(C=C(C=C1)O)C)=O JOFOAGSZQAGZDV-UHFFFAOYSA-N 0.000 description 1
- NCAFFUYLUZFZJF-UHFFFAOYSA-N 1-benzyl-3-[4-(4-hydroxyphenyl)azepan-1-yl]pyrrolidin-2-one Chemical compound C(C1=CC=CC=C1)N1C(C(CC1)N1CCC(CCC1)C1=CC=C(C=C1)O)=O NCAFFUYLUZFZJF-UHFFFAOYSA-N 0.000 description 1
- PHBBGHAXNTZALA-UHFFFAOYSA-N 1-benzyl-3-[4-(4-hydroxyphenyl)piperidin-1-yl]pyrrolidin-2-one Chemical compound C(C1=CC=CC=C1)N1C(C(CC1)N1CCC(CC1)C1=CC=C(C=C1)O)=O PHBBGHAXNTZALA-UHFFFAOYSA-N 0.000 description 1
- DGODCJUPOVOBKP-UHFFFAOYSA-N 1-benzyl-4-(4-methoxyphenyl)-3,6-dihydro-2h-pyridine Chemical compound C1=CC(OC)=CC=C1C(CC1)=CCN1CC1=CC=CC=C1 DGODCJUPOVOBKP-UHFFFAOYSA-N 0.000 description 1
- BBQQULRBTOMLTC-UHFFFAOYSA-N 1-benzylpiperidin-3-one Chemical compound C1C(=O)CCCN1CC1=CC=CC=C1 BBQQULRBTOMLTC-UHFFFAOYSA-N 0.000 description 1
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- ANLRSEYGSQEJAT-UHFFFAOYSA-N 2,2-dimethylpropanoic acid piperidine Chemical class N1CCCCC1.CC(C(=O)O)(C)C ANLRSEYGSQEJAT-UHFFFAOYSA-N 0.000 description 1
- RMLNZBLNEDHWOS-UHFFFAOYSA-N 2,4-dibromo-N-[(3-fluoro-4-methylphenyl)methyl]butanamide Chemical compound BrC(C(=O)NCC1=CC(=C(C=C1)C)F)CCBr RMLNZBLNEDHWOS-UHFFFAOYSA-N 0.000 description 1
- MCSJGXLZPITMIH-UHFFFAOYSA-N 2-aminobutane-1,1,1-triol Chemical compound CCC(N)C(O)(O)O MCSJGXLZPITMIH-UHFFFAOYSA-N 0.000 description 1
- QRYQFSUTOWIOMY-LGWYJFNUSA-N 3-[(3R,4R)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl]-1-(3-fluoro-4-methylphenyl)pyrrolidin-2-one Chemical compound F[C@H]1CN(CC[C@@H]1C1=CC=C(C=C1)O)C1C(N(CC1)C1=CC(=C(C=C1)C)F)=O QRYQFSUTOWIOMY-LGWYJFNUSA-N 0.000 description 1
- HFWJQXYJEYZULI-LKXRKSRJSA-N 3-[(3R,4R)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl]-1-[(2-methylphenyl)methyl]pyrrolidin-2-one Chemical compound F[C@H]1CN(CC[C@@H]1C1=CC=C(C=C1)O)C1C(N(CC1)CC1=C(C=CC=C1)C)=O HFWJQXYJEYZULI-LKXRKSRJSA-N 0.000 description 1
- MGQCKHMKECMTHK-LKXRKSRJSA-N 3-[(3R,4R)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl]-1-[(3-methylphenyl)methyl]pyrrolidin-2-one Chemical compound F[C@H]1CN(CC[C@@H]1C1=CC=C(C=C1)O)C1C(N(CC1)CC1=CC(=CC=C1)C)=O MGQCKHMKECMTHK-LKXRKSRJSA-N 0.000 description 1
- CAYQYXDBKVLPMB-XYDYXOPVSA-N 3-[(3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl]-1-(1-phenylethyl)pyrrolidin-2-one Chemical compound F[C@@H]1CN(CC[C@H]1C1=CC=C(C=C1)O)C1C(N(CC1)C(C)C1=CC=CC=C1)=O CAYQYXDBKVLPMB-XYDYXOPVSA-N 0.000 description 1
- HFWJQXYJEYZULI-UGGDCYSXSA-N 3-[(3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl]-1-[(2-methylphenyl)methyl]pyrrolidin-2-one Chemical compound F[C@@H]1CN(CC[C@H]1C1=CC=C(C=C1)O)C1C(N(CC1)CC1=C(C=CC=C1)C)=O HFWJQXYJEYZULI-UGGDCYSXSA-N 0.000 description 1
- MGQCKHMKECMTHK-UGGDCYSXSA-N 3-[(3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl]-1-[(3-methylphenyl)methyl]pyrrolidin-2-one Chemical compound F[C@@H]1CN(CC[C@H]1C1=CC=C(C=C1)O)C1C(N(CC1)CC1=CC(=CC=C1)C)=O MGQCKHMKECMTHK-UGGDCYSXSA-N 0.000 description 1
- QBTBTOLRDHNEQE-UHFFFAOYSA-N 3-[3-(4-hydroxyphenyl)azetidin-1-yl]-1-[(4-methylphenyl)methyl]pyrrolidin-2-one Chemical compound OC1=CC=C(C=C1)C1CN(C1)C1C(N(CC1)CC1=CC=C(C=C1)C)=O QBTBTOLRDHNEQE-UHFFFAOYSA-N 0.000 description 1
- IOZDYULPBYTTHU-UHFFFAOYSA-N 3-[3-(4-hydroxyphenyl)piperidin-1-yl]-1-[(4-methylphenyl)methyl]pyrrolidin-2-one Chemical compound CC1=CC=C(CN2C(C(CC2)N2CC(CCC2)C2=CC=C(C=C2)O)=O)C=C1 IOZDYULPBYTTHU-UHFFFAOYSA-N 0.000 description 1
- ZAIRIUOUQPUAPE-UHFFFAOYSA-N 3-[4-(4-hydroxyphenyl)azepan-1-yl]-1-[(4-methylphenyl)methyl]pyrrolidin-2-one Chemical compound OC1=CC=C(C=C1)C1CCN(CCC1)C1C(N(CC1)CC1=CC=C(C=C1)C)=O ZAIRIUOUQPUAPE-UHFFFAOYSA-N 0.000 description 1
- WKOQGHBYQWAKIH-LBOXEOMUSA-N 3-[4-(4-hydroxyphenyl)piperidin-1-yl]-1-[(1S)-1-phenylethyl]pyrrolidin-2-one Chemical compound OC1=CC=C(C=C1)C1CCN(CC1)C1C(N(CC1)[C@@H](C)C1=CC=CC=C1)=O WKOQGHBYQWAKIH-LBOXEOMUSA-N 0.000 description 1
- ILUHFPBBZNEUNW-UHFFFAOYSA-N 3-[4-(4-hydroxyphenyl)piperidin-1-yl]-1-[(4-methylphenyl)methyl]pyrrolidin-2-one Chemical compound OC1=CC=C(C=C1)C1CCN(CC1)C1C(N(CC1)CC1=CC=C(C=C1)C)=O ILUHFPBBZNEUNW-UHFFFAOYSA-N 0.000 description 1
- CFECXVZZKWKFAP-UHFFFAOYSA-N 3-bromo-1-[(3-fluoro-4-methylphenyl)methyl]pyrrolidin-2-one Chemical compound BrC1C(N(CC1)CC1=CC(=C(C=C1)C)F)=O CFECXVZZKWKFAP-UHFFFAOYSA-N 0.000 description 1
- OCOUYWVMAQNXJG-UHFFFAOYSA-N 3-bromo-1-[[4-(difluoromethyl)phenyl]methyl]pyrrolidin-2-one Chemical compound BrC1C(N(CC1)CC1=CC=C(C=C1)C(F)F)=O OCOUYWVMAQNXJG-UHFFFAOYSA-N 0.000 description 1
- UYUOSQHKFUCNQH-UHFFFAOYSA-N 3-hydroxy-3-(4-methoxyphenyl)azetidine-1-carboxylic acid Chemical compound COc1ccc(cc1)C1(O)CN(C1)C(O)=O UYUOSQHKFUCNQH-UHFFFAOYSA-N 0.000 description 1
- SCQNWDBELJSXBE-UHFFFAOYSA-N 4-(4-methoxy-2-methylphenyl)piperidine Chemical compound CC1=CC(OC)=CC=C1C1CCNCC1 SCQNWDBELJSXBE-UHFFFAOYSA-N 0.000 description 1
- VCRQRAYQLAPLJH-UHFFFAOYSA-N 4-(4-methoxyphenyl)piperidine Chemical compound C1=CC(OC)=CC=C1C1CCNCC1 VCRQRAYQLAPLJH-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- BFAOKRYYPAVBKX-UHFFFAOYSA-N 4-hydroxy-4-(4-methoxyphenyl)piperidine-1-carboxylic acid Chemical compound COc1ccc(cc1)C1(O)CCN(CC1)C(O)=O BFAOKRYYPAVBKX-UHFFFAOYSA-N 0.000 description 1
- FOWOXWLATUAFNQ-UHFFFAOYSA-N 4-oxopiperidine-1-carboxylic acid Chemical compound OC(=O)N1CCC(=O)CC1 FOWOXWLATUAFNQ-UHFFFAOYSA-N 0.000 description 1
- SJISCEAZUHNOMD-UHFFFAOYSA-N 4-phenylcyclohexan-1-amine Chemical compound C1CC(N)CCC1C1=CC=CC=C1 SJISCEAZUHNOMD-UHFFFAOYSA-N 0.000 description 1
- GPEOAEVZTOQXLG-UHFFFAOYSA-N 4-piperazin-1-ium-1-ylphenolate Chemical compound C1=CC(O)=CC=C1N1CCNCC1 GPEOAEVZTOQXLG-UHFFFAOYSA-N 0.000 description 1
- VRJHQPZVIGNGMX-UHFFFAOYSA-N 4-piperidinone Chemical compound O=C1CCNCC1 VRJHQPZVIGNGMX-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- CYSPWCARDHRYJX-UHFFFAOYSA-N 9h-fluoren-1-amine Chemical compound C12=CC=CC=C2CC2=C1C=CC=C2N CYSPWCARDHRYJX-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 229910015900 BF3 Inorganic materials 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000400611 Eucalyptus deanei Species 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 102100029458 Glutamate receptor ionotropic, NMDA 2A Human genes 0.000 description 1
- 102100022631 Glutamate receptor ionotropic, NMDA 2C Human genes 0.000 description 1
- 102100022626 Glutamate receptor ionotropic, NMDA 2D Human genes 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 102000034570 NR1 subfamily Human genes 0.000 description 1
- 108020001305 NR1 subfamily Proteins 0.000 description 1
- 108010054200 NR2B NMDA receptor Proteins 0.000 description 1
- 108091008644 NR2D Proteins 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010077495 Peptide oostatic hormone Proteins 0.000 description 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 102000003141 Tachykinin Human genes 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- SPTSIOTYTJZTOG-UHFFFAOYSA-N acetic acid;octadecanoic acid Chemical compound CC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O SPTSIOTYTJZTOG-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001409 amidines Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 150000003939 benzylamines Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- WOBLPDAWNVAVAS-UHFFFAOYSA-N butyl carboxy carbonate Chemical compound CCCCOC(=O)OC(O)=O WOBLPDAWNVAVAS-UHFFFAOYSA-N 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 229940125890 compound Ia Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000007267 depressive like behavior Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000006345 epimerization reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000012048 forced swim test Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 229930182480 glucuronide Natural products 0.000 description 1
- 150000008134 glucuronides Chemical class 0.000 description 1
- 108091008634 hepatocyte nuclear factors 4 Proteins 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 238000004896 high resolution mass spectrometry Methods 0.000 description 1
- 239000011539 homogenization buffer Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- QWXYZCJEXYQNEI-OSZHWHEXSA-N intermediate I Chemical compound COC(=O)[C@@]1(C=O)[C@H]2CC=[N+](C\C2=C\C)CCc2c1[nH]c1ccccc21 QWXYZCJEXYQNEI-OSZHWHEXSA-N 0.000 description 1
- ICIWUVCWSCSTAQ-UHFFFAOYSA-N iodic acid Chemical compound OI(=O)=O ICIWUVCWSCSTAQ-UHFFFAOYSA-N 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- OTCKOJUMXQWKQG-UHFFFAOYSA-L magnesium bromide Chemical compound [Mg+2].[Br-].[Br-] OTCKOJUMXQWKQG-UHFFFAOYSA-L 0.000 description 1
- 229910001623 magnesium bromide Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- RBWRWAUAVRMBAC-UHFFFAOYSA-M magnesium;methoxybenzene;bromide Chemical compound [Mg+2].[Br-].COC1=CC=[C-]C=C1 RBWRWAUAVRMBAC-UHFFFAOYSA-M 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Chemical group 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 229910052717 sulfur Chemical group 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
- 108060008037 tachykinin Proteins 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 108091008646 testicular receptors Proteins 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 229950005135 traxoprodil Drugs 0.000 description 1
- PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Substances COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- 206010047302 ventricular tachycardia Diseases 0.000 description 1
- 229950000339 xinafoate Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461925363P | 2014-01-09 | 2014-01-09 | |
| US61/925,363 | 2014-01-09 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201613884A TW201613884A (en) | 2016-04-16 |
| TWI640515B true TWI640515B (zh) | 2018-11-11 |
Family
ID=52463126
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW104100592A TWI640515B (zh) | 2014-01-09 | 2015-01-08 | 選擇性ｎｒ２ｂ拮抗劑 |
Country Status (28)
| Country | Link |
|---|---|
| US (10) | US9221796B2 (enExample) |
| EP (1) | EP3092224B1 (enExample) |
| JP (1) | JP6543259B2 (enExample) |
| KR (1) | KR102311518B1 (enExample) |
| CN (1) | CN106061961B (enExample) |
| AR (1) | AR099071A1 (enExample) |
| AU (1) | AU2015205001A1 (enExample) |
| CA (1) | CA2936293A1 (enExample) |
| CL (1) | CL2016001763A1 (enExample) |
| DK (1) | DK3092224T3 (enExample) |
| EA (1) | EA201691413A1 (enExample) |
| ES (1) | ES2693250T3 (enExample) |
| HR (1) | HRP20181585T1 (enExample) |
| HU (1) | HUE041986T2 (enExample) |
| IL (1) | IL246599A0 (enExample) |
| LT (1) | LT3092224T (enExample) |
| MX (1) | MX2016008898A (enExample) |
| PE (1) | PE20160933A1 (enExample) |
| PL (1) | PL3092224T3 (enExample) |
| PT (1) | PT3092224T (enExample) |
| RS (1) | RS57830B1 (enExample) |
| SG (1) | SG11201605618WA (enExample) |
| SI (1) | SI3092224T1 (enExample) |
| SM (1) | SMT201800619T1 (enExample) |
| TR (1) | TR201815579T4 (enExample) |
| TW (1) | TWI640515B (enExample) |
| UY (1) | UY35947A (enExample) |
| WO (1) | WO2015105772A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9221796B2 (en) * | 2014-01-09 | 2015-12-29 | Bristol-Myers Squibb Company | Selective NR2B antagonists |
| EP3303323B1 (en) * | 2015-06-01 | 2020-01-08 | Rugen Holdings (Cayman) Limited | 3,3-difluoropiperidine carbamate heterocyclic compounds as nr2b nmda receptor antagonists |
| AU2016340237A1 (en) * | 2015-10-14 | 2018-05-31 | Bristol-Myers Squibb Company | Selective NR2B antagonists |
| CA3001894A1 (en) | 2015-10-14 | 2017-04-20 | Bristol-Myers Squibb Company | Selective nr2b antagonists |
| CN108203404A (zh) * | 2018-03-02 | 2018-06-26 | 上海博邦医药科技有限公司 | (r)-3-苯基哌啶或/和(s)-3-苯基哌啶以及尼拉帕尼的手性中间体的合成方法 |
| US10781172B2 (en) | 2018-06-21 | 2020-09-22 | Northwestern University | Catalysts and methods for enantioselective conjugate additions of amines to unsaturated electrophiles |
| WO2024197289A1 (en) * | 2023-03-22 | 2024-09-26 | Gilgamesh Pharmaceuticals, Inc. | Negative allosteric modulators of glun2b receptors and methods of making and using the same |
| CN119504546B (zh) * | 2023-11-28 | 2025-12-05 | 成都地奥制药集团有限公司 | 内酰胺环类化合物及其用途 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001081295A1 (en) * | 2000-04-26 | 2001-11-01 | Warner-Lambert Company | Cyclohexylamine derivative as subtype selective nmda receptor antagonists |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2744448B1 (fr) | 1996-02-02 | 1998-04-24 | Pf Medicament | Nouvelles piperidines derivees d'aryl piperazine, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments |
| WO2000063173A1 (en) | 1999-04-14 | 2000-10-26 | F. Hoffmann-La Roche Ag | Process for the preparation of substituted piperidines |
| US6476041B1 (en) | 1999-10-29 | 2002-11-05 | Merck & Co., Inc. | 1,4 substituted piperidinyl NMDA/NR2B antagonists |
| WO2003035641A1 (en) | 2001-10-22 | 2003-05-01 | Shionogi & Co., Ltd. | Novel carbamoylpyrrolidone derivative |
| CN1798744A (zh) | 2003-06-04 | 2006-07-05 | 麦克公司 | 作为nmda/nr2b拮抗剂的3－氟－哌啶化合物 |
| BRPI0415113A (pt) | 2003-10-08 | 2006-11-28 | Pfizer | compostos de lactama condensados |
| US7935706B2 (en) | 2006-02-23 | 2011-05-03 | Shionogi & Co., Ltd. | Nitrogen-containing heterocycle derivatives substituted with cyclic group |
| EP2170334B1 (en) | 2007-06-29 | 2021-03-17 | Emory University | Nmda receptor antagonists for neuroprotection |
| US9221796B2 (en) * | 2014-01-09 | 2015-12-29 | Bristol-Myers Squibb Company | Selective NR2B antagonists |
-
2015
- 2015-01-05 US US14/589,205 patent/US9221796B2/en active Active
- 2015-01-06 HR HRP20181585TT patent/HRP20181585T1/hr unknown
- 2015-01-06 PT PT15703328T patent/PT3092224T/pt unknown
- 2015-01-06 DK DK15703328.3T patent/DK3092224T3/en active
- 2015-01-06 PL PL15703328T patent/PL3092224T3/pl unknown
- 2015-01-06 MX MX2016008898A patent/MX2016008898A/es unknown
- 2015-01-06 LT LTEP15703328.3T patent/LT3092224T/lt unknown
- 2015-01-06 SI SI201530408T patent/SI3092224T1/sl unknown
- 2015-01-06 CN CN201580012735.9A patent/CN106061961B/zh not_active Expired - Fee Related
- 2015-01-06 PE PE2016001107A patent/PE20160933A1/es not_active Application Discontinuation
- 2015-01-06 JP JP2016545819A patent/JP6543259B2/ja not_active Expired - Fee Related
- 2015-01-06 HU HUE15703328A patent/HUE041986T2/hu unknown
- 2015-01-06 SG SG11201605618WA patent/SG11201605618WA/en unknown
- 2015-01-06 CA CA2936293A patent/CA2936293A1/en not_active Abandoned
- 2015-01-06 EA EA201691413A patent/EA201691413A1/ru unknown
- 2015-01-06 TR TR2018/15579T patent/TR201815579T4/tr unknown
- 2015-01-06 EP EP15703328.3A patent/EP3092224B1/en active Active
- 2015-01-06 AU AU2015205001A patent/AU2015205001A1/en not_active Abandoned
- 2015-01-06 WO PCT/US2015/010262 patent/WO2015105772A1/en not_active Ceased
- 2015-01-06 SM SM20180619T patent/SMT201800619T1/it unknown
- 2015-01-06 RS RS20181296A patent/RS57830B1/sr unknown
- 2015-01-06 KR KR1020167021356A patent/KR102311518B1/ko not_active Expired - Fee Related
- 2015-01-06 ES ES15703328.3T patent/ES2693250T3/es active Active
- 2015-01-08 TW TW104100592A patent/TWI640515B/zh not_active IP Right Cessation
- 2015-01-09 UY UY0001035947A patent/UY35947A/es unknown
- 2015-01-09 AR ARP150100065A patent/AR099071A1/es unknown
- 2015-10-13 US US14/882,041 patent/US20160081995A1/en not_active Abandoned
-
2016
- 2016-07-04 IL IL246599A patent/IL246599A0/en unknown
- 2016-07-08 CL CL2016001763A patent/CL2016001763A1/es unknown
-
2017
- 2017-05-25 US US15/604,904 patent/US20170258777A1/en not_active Abandoned
- 2017-09-15 US US15/706,172 patent/US20180000807A1/en not_active Abandoned
- 2017-12-19 US US15/846,672 patent/US20180110766A1/en not_active Abandoned
-
2018
- 2018-05-04 US US15/971,067 patent/US20180250283A1/en not_active Abandoned
- 2018-12-19 US US16/225,850 patent/US20190117638A1/en not_active Abandoned
-
2019
- 2019-06-27 US US16/454,831 patent/US20190314358A1/en not_active Abandoned
-
2020
- 2020-01-30 US US16/777,114 patent/US20200163949A1/en not_active Abandoned
- 2020-09-04 US US17/012,781 patent/US20210121453A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001081295A1 (en) * | 2000-04-26 | 2001-11-01 | Warner-Lambert Company | Cyclohexylamine derivative as subtype selective nmda receptor antagonists |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI640515B (zh) | 選擇性ｎｒ２ｂ拮抗劑 | |
| CN107660199B (zh) | 哌嗪氨基甲酸酯及其制备和使用方法 | |
| JP2022550640A (ja) | Ｋｖ１．３カリウムシェーカーチャネル遮断薬としてのアリール複素環式化合物 | |
| CN103097364A (zh) | 作为s1p调节剂的螺-哌啶衍生物 | |
| EP3362447B1 (en) | Selective nr2b antagonists | |
| CN113950477B (zh) | 颗粒体蛋白前体调节剂和其使用方法 | |
| TW201609716A (zh) | 六氫吡□衍生物及其作為藥物之用途 | |
| JP6629738B2 (ja) | 精神障害の治療のための（ｒ）−３−（（３ｓ，４ｓ）−３−フルオロ−４−（４−ヒドロキシフェニル）ピペリジン−１−イル）−１−（４−メチルベンジル）ピロリジン−２−オンおよびそのプロドラッグ | |
| JP7349570B2 (ja) | Ｍ４作動薬としての２－アザスピロ［３．４］オクタン誘導体 | |
| KR20110091501A (ko) | 니코틴성 아세틸콜린 수용체 리간드 및 이들의 용도 | |
| JP2025186255A (ja) | Ｋｖ１．３カリウムシェーカーチャネル遮断薬としてのアリール複素環式化合物 | |
| HK1184153B (en) | Spiro-cyclic amine derivatives as s1p modulators |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |